Contact your health care provider right away if you have any of the following symptoms that could be signs of lactic acidosis:
Contact your health care provider right away if you have any of the following symptoms that could be signs of liver problems:
People infected with hepatitis B virus (HBV) who take emtricitabine and then stop taking it may get severe worsening of their HBV infections. Do not stop taking emtricitabine without first talking with your health care provider. For information about the use of emtricitabine as part of combination antiretroviral therapy (ART) to treat HBV infection in people with HIV, see the “What is emtricitabine?” section below.
While taking emtricitabine, it is important to keep all of your appointments with your health care provider.
Emtricitabine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults, children, and infants. Emtricitabine is always used in combination with other HIV medicines.
Emtricitabine belongs to a class (group) of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs). NRTIs block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking reverse transcriptase, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.
HIV medicines can’t cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission. If you are taking HIV medicines, including emtricitabine, don’t cut down on, skip, or stop taking them unless your health care provider tells you to.
Because emtricitabine is also effective against HBV, it may be included in an HIV regimen to treat HBV infection in people with HIV. In addition to emtricitabine, the HIV regimen should include another drug that is effective against both HBV and HIV. Emtricitabine should not be used to treat HBV infection in HIV-infected individuals who are not receiving ART. For information on the HBV-related use of emtricitabine, please refer to the HBV section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.
Before taking emtricitabine, tell your health care provider:
Emtricitabine (brand name: Emtriva) comes in the following forms and strengths:
Take emtricitabine according to your health care provider’s instructions.
Take emtricitabine by mouth, with or without food.
Always take emtricitabine in combination with other HIV medicines.
If you take too much emtricitabine, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.
For more information on how to take emtricitabine, see the FDA drug label from DailyMed. (DailyMed is a federal website that includes the most recent drug labels submitted to FDA.)
If you miss a dose of emtricitabine, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take more than one dose of emtricitabine in a day. Do not take two doses at the same time to make up for a missed dose.
Emtricitabine may cause side effects. Most side effects from emtricitabine are manageable, but a few can be serious. Serious side effects of emtricitabine include lactic acidosis (buildup of lactic acid in the blood) and serious liver problems. (See the WARNING above.)
Other possible side effects of emtricitabine include:
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of emtricitabine. To learn more about possible side effects of emtricitabine, read the drug label or package insert or talk to your health care provider or pharmacist.
The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to emtricitabine.
You can also report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online at https://www.accessdata.fda.gov/scripts/medwatch/.
More information about emtricitabine is available:
Gilead Sciences, Inc.
Last Reviewed: November 23, 2015